Anticoagulants for Atrial Fibrillation in Survivors of Intracranial Hemorrhage
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Anticoagulants for Atrial Fibrillation in Survivors of Intracranial Hemorrhage: A Meta-Analysis of Randomized Trials: JACCJournals. New publication from our HeartWise research Group led by friend: Michael Nanna in JACC today!”
RVRoland VeltkampProfessor of neurology, Imperial College London
“Because ICH survivors with AF have a high risk of ischemic stroke, they are in need of effective preventive treatments. DOACs effectively reduced the risk of ischemic stroke and of other ischemic events in PRESTIGE-AF; however, a part of this benefit was offset by major bleeding side effects of DOACs, in particular recurrent ICH.”
“This trial was really important because it was the largest published trial to date that starts to give us high-quality scientific estimates on these endpoints.”
Abstract
No abstract yet. The journal hasn't published one we can show.
Coverage & sources
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Chi et al. (2025) studied this question.